Navigation Links
Nutraceutical Reports Fiscal 2008 Q1 Results
Date:1/31/2008

copies of which are available upon request from our investor relations group or which may be obtained at the SEC's website (http://www.sec.gov).

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

December 31, September 30,

2007 2007

Assets

Current assets, net $49,904 $51,534

Property, plant and equipment, net 42,367 39,506

Goodwill 39,066 38,978

Other non-current assets, net 15,898 16,384

$147,235 $146,402

Liabilities and Stockholders' Equity

Current liabilities $17,725 $20,275

Long-term liabilities 21,227 20,208

Stockholders' equity 108,283 105,919

$147,235 $146,402

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

Three months ended December 31,

2007 2006

Net sales $41,086 $35,848

Cost of sales 18,773 16,324

Gross profit 22,313 19,524

Operating expenses

Selling, general and administrative 16,628 13,922

<
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
3. Nutraceutical Reports 2007 Fiscal Year End Results
4. New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs
5. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
6. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
7. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
8. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
9. Encision Reports Third Fiscal Quarter Results
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Amylin Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...udy released this week showing that a growing numb...c diseases shines a much-needed spotlight on the n...at focuses on primary and secondary prevention, ac... disease prevention. , , (Logo: http://www...., , The study, conducted by Social & Scient...
(Date:1/8/2009)...chle at his confirmation hearing to be the next Se...SHINGTON, Jan. 8 Bipart...ator Tom Daschle, nominee for Department of Health...ellow BPC founder and friend Senator Bob Dole at h...vened by the Senate Health, Education, Labor, and ...
(Date:1/8/2009)...earch Hospital have demonstrated a more effective ...nza. They found that the antibiotics clindamycin a... their protein synthesis, are more effective than ...tam" antibiotic ampicillin, which causes the bacte...ant because pneumonia, rather than the influenza i...
(Date:1/8/2009)...re-FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN...t and chief,executive officer, will present at th...n Wednesday, January 14, at 10:00 a.m. Pacific Tim...o. , Dr. Hung will provide an overview of M...or Dimebon for Alzheimer,s and Huntington,s diseas...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...ine has been shrouded in controversy. Now, Britain...alled for an end to the raging //debates over this...public that warns of a threat to young lives by fo...They have appealed to the politicians, healthcare ...
...lison, a University of Alabama biostatistician has...ons for obesity. //He was assisted in this venture...da and Italy. The researchers looked at more than... besides exercise and diet. They found that the fo...
... is on the rise in New Zealand. Hence Pharmac deci...se who have serious fluctuations in blood sugar le...r Lantus at a subsidized rate from July 1. Murra... the Diabetes New Zealand said that they have work...
...rays of women with high-risk genes could increase ...archers led by David Goldgar // at the Internation...d 1,600 women. He found that women with BRCA1 and ... mutations who had undergone a chest X-ray were 54...
Other Medicine News:
(Date:1/8/2009)...EUVEN, Belgium, January 9 /PRNewswire-FirstCall/ -...died in the Treatment of,Vitreomacular Adhesion i...onext Brussels: THR), a biotechnology company,foc...cular disease and,cancer, announces today that it...croplasmin for the non-surgical treatment of back ...
(Date:1/8/2009)...HICAGO, Jan. 8 If you are taking p... you,re not alone. Half of the people taking,pres... reasons are,varied -- they forget, are busy with...ot to. Noncompliance has been called the Achilles ...ral Everett Koop commented, "Drugs don,t,work in ...
(Date:1/7/2009)...NDIANAPOLIS, Jan. 7 Eli ...that it received a complete response letter from,...anzapine long-acting,injection (LAI) for acute an...s. Lilly is continuing to work with the agency on ...does not require any additional clinical trials fo...
(Date:1/7/2009)...RICK, Md., Jan. 7 ImQuest Life Sci... an IND application to the Food and Drug Administr...lead pyrimidinedione HIV inhibitor IQP-0410. ImQue... the first quarter of 2009. IQP-0410 is a novel sm... as a nonnucleoside reverse transcriptase inhibito...
Breaking Medicine Technology:ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Good Medicine: Smarter Smartphones for People With Chronic Disease 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Delaware Man Spearheads Brain Tumor Awareness 7970 1Delaware Man Spearheads Brain Tumor Awareness 7970 2Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 1Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 2New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 1New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 1Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 3Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 4Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 5
...jection of peramivir for eight,days protected mice...hibited virus replication, supporting the use of t...EMPHIS, Tenn., May 01, 2007 /PRNewswire-USNewswire...ns significant protection,during a pandemic of the...of mouse studies conducted by investigators at St....
...ESS WIRE)--May 1, 2007 - Teva,Pharmaceutical Indus...hat data from a 36-week, randomized, double-blind,...hat an oral 0.6 mg,dose of laquinimod given daily ...MRI) disease activity by 38 percent in RRMS,patien...a favorable,trend towards reducing annual relapse ...
Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2Peramivir Protects Mice From Lethal H5N1 Infection 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
...ECHET EXTENDER® is a new device for skin exten... elastomer strips, it allows a constant and powerf...r devices capacities. Such effectiveness makes the...it is removed before 30 days. Furthermore it is in...
Inquire
Inquire
Medicine Products: